| Literature DB >> 17721108 |
Doris Chibo1, Norman Roth, Vanessa Roulet, Katharina Skrabal, Megan Gooey, Louise Carolan, Jodie Nicholls, Anastasia Papadakis, Chris Birch.
Abstract
Resistance to the HIV fusion inhibitor enfuvirtide is associated with mutations in the first heptad repeat region of gp41, but little is known of their impact on replicative fitness in vivo. We followed seven patients undergoing salvage therapy that included enfuvirtide in order to document the temporal generation of genotypic and phenotypic resistance in parallel with replicative fitness. Resistance to enfuvirtide was not associated with decreased replicative fitness of HIV strains infecting these patients.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17721108 DOI: 10.1097/QAD.0b013e3282ef1bc8
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177